Dr. Neidhart is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2325 E 30th St
Farmington, NM 87401Phone+1 505-564-6850Fax+1 505-564-6890
Education & Training
University of Alabama Medical CenterFellowship, Hematology and Medical Oncology, 1999 - 2002
Ohio State University HospitalResidency, Internal Medicine, 1995 - 1998
University of New Mexico School of MedicineClass of 1995
Certifications & Licensure
NM State Medical License 2002 - 2026
CO State Medical License 2002 - 2025
AL State Medical License 1999 - 2024
OH State Medical License 1996 - 2022- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification MOSAIQ EMR, Elekta, 2012
Clinical Trials
- Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors Start of enrollment: 2006 May 01
- Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer Start of enrollment: 2014 May 01
Publications & Presentations
PubMed
- 128 citationsFirst-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignanciesGlen J. Weiss, Joseph Chao, Jeffrey D. Neidhart, Ramesh K. Ramanathan, Dawn Bassett
Investigational New Drugs. 2013-02-09 - 32 citationsA randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquam...Edward B. Garon, Jeffrey D. Neidhart, Nashat Y Gabrail, Moacyr Ribeiro de Oliveira, Jai Balkissoon
Oncotargets and Therapy. 2016-11-30 - 44 citationsImmunization of colorectal cancer patients with recombinant baculovirus-derived KSA (Ep-CAM) formulated with monophosphoryl lipid A in liposomal emulsion, with and wit...Jeffrey Neidhart, Karen O. Allen, Daunte L. Barlow, Mark Carpenter, Denise R. Shaw
Vaccine. 2004-01-01
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
